SCHEDULES
C1I1SCHEDULE 13Tax relief for expenditure on vaccine research etc
Sch. 13 modified (with effect as specified in art. 2 of the commencing S.I. of the commencing S.I.) by Finance Act 2004 (c. 12), s. 53(2)(6); S.I. 2004/3268, art. 2
Part 1Entitlement to relief
4Qualifying R&D activity
1
For the purposes of this Schedule “qualifying R&D activity” means research and development relating to—
a
vaccines or medicines for the prevention or treatment of tuberculosis,
b
vaccines or medicines for the prevention or treatment of malaria,
c
vaccines for the prevention of infection by human immunodeficiency virus, or
d
vaccines or medicines for the prevention of the onset, or for the treatment, of acquired immune deficiency syndrome resulting from infection by human immunodeficiency virus in prescribed clades only.
2
For the purposes of sub-paragraph (1) “prescribed clade” means clade A, C, D or E or such other clade or clades as the Treasury may by regulations prescribe.
3
The Treasury may make provision by regulations further defining the purposes referred to in sub-paragraph (1)(a), (b), (c) or (d).
4
In sub-paragraph (1) references to vaccines or medicines are to vaccines or medicines for use in humans.
Sch. 13 has effect in relation to expenditure incurred on or after 22.4.2003 by The Finance Act 2002, Schedule 13 (Appointed Day) Order 2003 (S.I. 2003/1472), art. 2 (with para. 28(1))